Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 663

1.

Only 8% of major preventable adverse events after hip arthroplasty are filed as claims: a Swedish multi-center cohort study on 1,998 patients.

Magnéli M, Unbeck M, Samuelsson B, Rogmark C, Rolfson O, Gordon M, Sköldenberg O.

Acta Orthop. 2019 Oct 16:1-6. doi: 10.1080/17453674.2019.1677382. [Epub ahead of print]

PMID:
31615309
2.

Pedro Brugada and Peter Schwartz share the Lefoulon-Delalande Foundation Scientific Prize 2019.

Alto K, Carpentier A, de Gaetano G, Gros F, Haissaguerre M, Lazdunski M, Nemer M, Noble D, Sabatini DD, Samuelsson B, Taylor DA.

Eur Heart J. 2019 Aug 21;40(32):2670. doi: 10.1093/eurheartj/ehz597. No abstract available.

PMID:
31433852
3.

The influence of depression on patient-reported outcomes for hip-fracture patients 1 year after surgery: a prospective cohort study.

Kelly-Pettersson P, Samuelsson B, Unbeck M, Muren O, Magnéli M, Gordon M, Stark A, Sköldenberg O.

Aging Clin Exp Res. 2019 Apr 26. doi: 10.1007/s40520-019-01207-5. [Epub ahead of print]

PMID:
31028625
4.

Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study.

Magnéli M, Unbeck M, Rogmark C, Rolfson O, Hommel A, Samuelsson B, Schildmeijer K, Sjöstrand D, Gordon M, Sköldenberg O.

BMJ Open. 2019 Mar 7;9(3):e023773. doi: 10.1136/bmjopen-2018-023773.

5.

Exosomes and cells from lung cancer pleural exudates transform LTC4 to LTD4, promoting cell migration and survival via CysLT1.

Lukic A, Wahlund CJE, Gómez C, Brodin D, Samuelsson B, Wheelock CE, Gabrielsson S, Rådmark O.

Cancer Lett. 2019 Mar 1;444:1-8. doi: 10.1016/j.canlet.2018.11.033. Epub 2018 Dec 1.

PMID:
30508568
6.

Pillars Article: Leukotriene C: A Slow-Reacting Substance from Murine Mastocytoma Cells. Proc. Natl. Acad. Sci. USA. 1979. 76: 4275-4279.

Murphy RC, Hammarström S, Samuelsson B.

J Immunol. 2018 Mar 1;200(5):1538-1542. No abstract available.

7.

Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.

Di Gennaro A, Araújo AC, Busch A, Jin H, Wågsäter D, Vorkapic E, Caidahl K, Eriksson P, Samuelsson B, Maegdefessel L, Haeggström JZ.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1907-1912. doi: 10.1073/pnas.1717906115. Epub 2018 Feb 5.

8.

Capturing LTA4 hydrolase in action: Insights to the chemistry and dynamics of chemotactic LTB4 synthesis.

Stsiapanava A, Samuelsson B, Haeggström JZ.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9689-9694. doi: 10.1073/pnas.1710850114. Epub 2017 Aug 21.

9.

Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males.

Pace S, Pergola C, Dehm F, Rossi A, Gerstmeier J, Troisi F, Pein H, Schaible AM, Weinigel C, Rummler S, Northoff H, Laufer S, Maier TJ, Rådmark O, Samuelsson B, Koeberle A, Sautebin L, Werz O.

J Clin Invest. 2017 Aug 1;127(8):3167-3176. doi: 10.1172/JCI92885. Epub 2017 Jul 24.

10.

GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures.

Lukic A, Larssen P, Fauland A, Samuelsson B, Wheelock CE, Gabrielsson S, Radmark O.

FASEB J. 2017 Oct;31(10):4370-4381. doi: 10.1096/fj.201700319R. Epub 2017 Jun 21.

PMID:
28637652
11.

Normal gastric emptying time of a carbohydrate-rich drink in elderly patients with acute hip fracture: a pilot study.

Hellström PM, Samuelsson B, Al-Ani AN, Hedström M.

BMC Anesthesiol. 2017 Feb 15;17(1):23. doi: 10.1186/s12871-016-0299-6.

12.

Waiting time to surgery is correlated with an increased risk of serious adverse events during hospital stay in patients with hip-fracture: A cohort study.

Kelly-Pettersson P, Samuelsson B, Muren O, Unbeck M, Gordon M, Stark A, Sköldenberg O.

Int J Nurs Stud. 2017 Apr;69:91-97. doi: 10.1016/j.ijnurstu.2017.02.003. Epub 2017 Feb 6.

PMID:
28189926
13.

Pulmonary epithelial cancer cells and their exosomes metabolize myeloid cell-derived leukotriene C4 to leukotriene D4.

Lukic A, Ji J, Idborg H, Samuelsson B, Palmberg L, Gabrielsson S, Rådmark O.

J Lipid Res. 2016 Sep;57(9):1659-69. doi: 10.1194/jlr.M066910. Epub 2016 Jul 19.

14.

A dynamic Asp-Arg interaction is essential for catalysis in microsomal prostaglandin E2 synthase.

Brock JS, Hamberg M, Balagunaseelan N, Goodman M, Morgenstern R, Strandback E, Samuelsson B, Rinaldo-Matthis A, Haeggström JZ.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):972-7. doi: 10.1073/pnas.1522891113. Epub 2016 Jan 11.

15.

Sex effects on short-term complications after hip fracture: a prospective cohort study.

Ekström W, Samuelsson B, Ponzer S, Cederholm T, Thorngren KG, Hedström M.

Clin Interv Aging. 2015 Aug 5;10:1259-66. doi: 10.2147/CIA.S80100. eCollection 2015.

16.

Sjukvård på gränsen till fiendeland.

Samuelsson K, Lagercrantz H, Lindahl S, Philipson A, Samuelsson B.

Lakartidningen. 2015 Jun 24;112. pii: DLCZ. Swedish. No abstract available.

17.

Design and Synthesis of Novel Arylketo-containing P1-P3 Linked Macro-cyclic BACE-1 Inhibitors.

Sandgren V, Belda O, Kvarnström I, Lindberg J, Samuelsson B, Dahlgren A.

Open Med Chem J. 2015 Mar 31;9:13-26. doi: 10.2174/1874104501509010013. eCollection 2015.

18.

5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease.

Rådmark O, Werz O, Steinhilber D, Samuelsson B.

Biochim Biophys Acta. 2015 Apr;1851(4):331-9. doi: 10.1016/j.bbalip.2014.08.012. Epub 2014 Aug 22. Review.

PMID:
25152163
19.

Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis.

Basavarajappa D, Wan M, Lukic A, Steinhilber D, Samuelsson B, Rådmark O.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11371-6. doi: 10.1073/pnas.1410983111. Epub 2014 Jul 17.

20.

Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.

Stsiapanava A, Olsson U, Wan M, Kleinschmidt T, Rutishauser D, Zubarev RA, Samuelsson B, Rinaldo-Matthis A, Haeggström JZ.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4227-32. doi: 10.1073/pnas.1402136111. Epub 2014 Mar 3.

21.

A mutation interfering with 5-lipoxygenase domain interaction leads to increased enzyme activity.

Rakonjac Ryge M, Tanabe M, Provost P, Persson B, Chen X, Funk CD, Rinaldo-Matthis A, Hofmann B, Steinhilber D, Watanabe T, Samuelsson B, Rådmark O.

Arch Biochem Biophys. 2014 Mar 1;545:179-85. doi: 10.1016/j.abb.2014.01.017. Epub 2014 Jan 28.

PMID:
24480307
22.

Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.

Rosenquist Å, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-Mauviel M.

J Med Chem. 2014 Mar 13;57(5):1673-93. doi: 10.1021/jm401507s. Epub 2014 Feb 14.

PMID:
24446688
23.

Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.

Jonckers TH, Vandyck K, Vandekerckhove L, Hu L, Tahri A, Van Hoof S, Lin TI, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Leclercq L, Fanning G, Samuelsson B, Nilsson M, Rosenquist Å, Simmen K, Raboisson P.

J Med Chem. 2014 Mar 13;57(5):1836-44. doi: 10.1021/jm4015422. Epub 2014 Jan 6.

PMID:
24345201
24.

Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.

Joshi A, Véron JB, Unge J, Rosenquist Å, Wallberg H, Samuelsson B, Hallberg A, Larhed M.

J Med Chem. 2013 Nov 27;56(22):8999-9007. doi: 10.1021/jm400811d. Epub 2013 Nov 11.

25.

Risk factors for osteoporosis are common in young and middle-aged patients with femoral neck fractures regardless of trauma mechanism.

Al-Ani AN, Neander G, Samuelsson B, Blomfeldt R, Ekström W, Hedström M.

Acta Orthop. 2013 Feb;84(1):54-9. doi: 10.3109/17453674.2013.765639. Epub 2013 Jan 23.

26.

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.

Kesteleyn B, Amssoms K, Schepens W, Hache G, Verschueren W, Van De Vreken W, Rombauts K, Meurs G, Sterkens P, Stoops B, Baert L, Austin N, Wegner J, Masungi C, Dierynck I, Lundgren S, Jönsson D, Parkes K, Kalayanov G, Wallberg H, Rosenquist A, Samuelsson B, Van Emelen K, Thuring JW.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):310-7. doi: 10.1016/j.bmcl.2012.10.095. Epub 2012 Nov 1.

PMID:
23177258
27.

Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes.

Sandgren V, Agback T, Johansson PO, Lindberg J, Kvarnström I, Samuelsson B, Belda O, Dahlgren A.

Bioorg Med Chem. 2012 Jul 15;20(14):4377-89. doi: 10.1016/j.bmc.2012.05.039. Epub 2012 May 24.

PMID:
22698785
28.

Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication.

Nilsson M, Kalayanov G, Winqvist A, Pinho P, Sund C, Zhou XX, Wähling H, Belfrage AK, Pelcman M, Agback T, Benckestock K, Wikström K, Boothee M, Lindqvist A, Rydegård C, Jonckers TH, Vandyck K, Raboisson P, Lin TI, Lachau-Durand S, de Kock H, Smith DB, Martin JA, Klumpp K, Simmen K, Vrang L, Terelius Y, Samuelsson B, Rosenquist S, Johansson NG.

Bioorg Med Chem Lett. 2012 May 1;22(9):3265-8. doi: 10.1016/j.bmcl.2012.03.021. Epub 2012 Mar 16.

PMID:
22472694
29.

Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.

Wu X, Ohrngren P, Joshi AA, Trejos A, Persson M, Arvela RK, Wallberg H, Vrang L, Rosenquist A, Samuelsson BB, Unge J, Larhed M.

J Med Chem. 2012 Mar 22;55(6):2724-36. doi: 10.1021/jm201620t. Epub 2012 Mar 13.

30.

Role of basic science in the development of new medicines: examples from the eicosanoid field.

Samuelsson B.

J Biol Chem. 2012 Mar 23;287(13):10070-80. doi: 10.1074/jbc.X112.351437. Epub 2012 Feb 8. Review.

31.

Targeted knock-down of a structurally atypical zebrafish 12S-lipoxygenase leads to severe impairment of embryonic development.

Haas U, Raschperger E, Hamberg M, Samuelsson B, Tryggvason K, Haeggström JZ.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20479-84. doi: 10.1073/pnas.1117094108. Epub 2011 Dec 5.

32.

Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Berke JM, Vijgen L, Lachau-Durand S, Powdrill MH, Rawe S, Sjuvarsson E, Eriksson S, Götte M, Fransen E, Dehertogh P, Van den Eynde C, Leclercq L, Jonckers TH, Raboisson P, Nilsson M, Samuelsson B, Rosenquist Å, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2011 Aug;55(8):3812-20. doi: 10.1128/AAC.00214-11. Epub 2011 May 16.

33.

Zymosan suppresses leukotriene C₄ synthase activity in differentiating monocytes: antagonism by aspirin and protein kinase inhibitors.

Esser J, Gehrmann U, Salvado MD, Wetterholm A, Haeggström JZ, Samuelsson B, Gabrielsson S, Scheynius A, Rådmark O.

FASEB J. 2011 Apr;25(4):1417-27. doi: 10.1096/fj.10-175828. Epub 2011 Jan 12.

PMID:
21228223
34.

Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors.

Wångsell F, Nordeman P, Sävmarker J, Emanuelsson R, Jansson K, Lindberg J, Rosenquist S, Samuelsson B, Larhed M.

Bioorg Med Chem. 2011 Jan 1;19(1):145-55. doi: 10.1016/j.bmc.2010.11.042. Epub 2010 Nov 26.

PMID:
21183353
35.

Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.

Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G, Nilsson NÖ, Samuelsson BO, Wood T, Aman J, Ortqvist E, Casas R.

Diabetologia. 2011 Mar;54(3):634-40. doi: 10.1007/s00125-010-1988-1. Epub 2010 Nov 30.

PMID:
21116604
36.

Design and synthesis of potent macrocyclic renin inhibitors.

Sund C, Belda O, Wiktelius D, Sahlberg C, Vrang L, Sedig S, Hamelink E, Henderson I, Agback T, Jansson K, Borkakoti N, Derbyshire D, Eneroth A, Samuelsson B.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):358-62. doi: 10.1016/j.bmcl.2010.10.140. Epub 2010 Nov 5.

PMID:
21112780
37.

Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm.

Di Gennaro A, Wågsäter D, Mäyränpää MI, Gabrielsen A, Swedenborg J, Hamsten A, Samuelsson B, Eriksson P, Haeggström JZ.

Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21093-7. doi: 10.1073/pnas.1015166107. Epub 2010 Nov 15.

38.

2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.

Jonckers TH, Lin TI, Buyck C, Lachau-Durand S, Vandyck K, Van Hoof S, Vandekerckhove LA, Hu L, Berke JM, Vijgen L, Dillen LL, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegård C, Samuelsson B, Rosenquist A, Fanning G, Van Emelen K, Simmen K, Raboisson P.

J Med Chem. 2010 Nov 25;53(22):8150-60. doi: 10.1021/jm101050a. Epub 2010 Oct 29.

PMID:
21033671
39.

The structural basis of blood group A-related glycolipids in an A3 red cell phenotype and a potential explanation to a serological phenomenon.

Svensson L, Bindila L, Angström J, Samuelsson BE, Breimer ME, Rydberg L, Henry SM.

Glycobiology. 2011 Feb;21(2):162-74. doi: 10.1093/glycob/cwq143. Epub 2010 Oct 6.

PMID:
20926599
40.

Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.

Nilsson M, Belfrage AK, Lindström S, Wähling H, Lindquist C, Ayesa S, Kahnberg P, Pelcman M, Benkestock K, Agback T, Vrang L, Terelius Y, Wikström K, Hamelink E, Rydergård C, Edlund M, Eneroth A, Raboisson P, Lin TI, de Kock H, Wigerinck P, Simmen K, Samuelsson B, Rosenquist S.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4004-11. doi: 10.1016/j.bmcl.2010.05.029. Epub 2010 May 21.

PMID:
20541405
41.

Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer.

Rådmark O, Samuelsson B.

J Intern Med. 2010 Jul;268(1):5-14. doi: 10.1111/j.1365-2796.2010.02246.x. Epub 2010 Apr 28. Review.

42.

Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis.

Rådmark O, Samuelsson B.

Biochem Biophys Res Commun. 2010 May 21;396(1):105-10. doi: 10.1016/j.bbrc.2010.02.173. Review.

PMID:
20494120
43.

Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.

Cummings MD, Lindberg J, Lin TI, de Kock H, Lenz O, Lilja E, Felländer S, Baraznenok V, Nyström S, Nilsson M, Vrang L, Edlund M, Rosenquist A, Samuelsson B, Raboisson P, Simmen K.

Angew Chem Int Ed Engl. 2010 Feb 22;49(9):1652-5. doi: 10.1002/anie.200906696. No abstract available. Erratum in: Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3250.

PMID:
20166108
44.

Design and synthesis of potent and selective BACE-1 inhibitors.

Björklund C, Oscarson S, Benkestock K, Borkakoti N, Jansson K, Lindberg J, Vrang L, Hallberg A, Rosenquist A, Samuelsson B.

J Med Chem. 2010 Feb 25;53(4):1458-64. doi: 10.1021/jm901168f.

PMID:
20128595
45.

Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.

Björklund C, Adolfsson H, Jansson K, Lindberg J, Vrang L, Hallberg A, Rosenquist S, Samuelsson B.

Bioorg Med Chem. 2010 Feb 15;18(4):1711-23. doi: 10.1016/j.bmc.2009.12.051. Epub 2010 Jan 11.

PMID:
20122837
46.

The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.

Fuller K, Lindstrom E, Edlund M, Henderson I, Grabowska U, Szewczyk KA, Moss R, Samuelsson B, Chambers TJ.

Bone. 2010 May;46(5):1400-7. doi: 10.1016/j.bone.2010.01.374. Epub 2010 Jan 25.

PMID:
20097319
47.

Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.

Wångsell F, Gustafsson K, Kvarnström I, Borkakoti N, Edlund M, Jansson K, Lindberg J, Hallberg A, Rosenquist A, Samuelsson B.

Eur J Med Chem. 2010 Mar;45(3):870-82. doi: 10.1016/j.ejmech.2009.11.013. Epub 2009 Nov 12.

PMID:
20036448
48.

P2'-truncated BACE-1 inhibitors with a novel hydroxethylene-like core.

Meredith JA, Björklund C, Adolfsson H, Jansson K, Hallberg A, Rosenquist A, Samuelsson B.

Eur J Med Chem. 2010 Feb;45(2):542-54. doi: 10.1016/j.ejmech.2009.10.041. Epub 2009 Nov 3.

PMID:
19995674
49.

HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, Kihlström J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.

J Med Chem. 2010 Jan 28;53(2):607-15. doi: 10.1021/jm901165g.

PMID:
19961222
50.

Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.

Adrian Meredith J, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B.

Eur J Med Chem. 2010 Jan;45(1):160-70. doi: 10.1016/j.ejmech.2009.09.038. Epub 2009 Oct 6.

PMID:
19926360

Supplemental Content

Loading ...
Support Center